Extended Data Table 3 Analysis of covariance of the dose-normalized area under the serum concentration–time curve over the dosing interval (AUCtau) following 2 mg and 10 mg Q4W dosing of budigalimab in Stage I

From: Budigalimab, an anti-PD-1 inhibitor, for people living with HIV-1: a randomized, placebo-controlled phase 1b study